<DOC>
	<DOCNO>NCT00327808</DOCNO>
	<brief_summary>The investigator look TPI-1020 safety tolerability mild moderate asthmatic smoker subject .</brief_summary>
	<brief_title>Inhaled TPI-1020 Versus Inhaled Budesonide Smokers With Mild Reversible Asthma</brief_title>
	<detailed_description>This study ass compare safety tolerability inhale TPI 1020 versus budesonide . Pharmacokinetic ( PK ) pharmacodynamic ( PD ) parameter also study sub-group subject .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Males females 18 65 year age . Smoking history 5 pack/years less 25 pack/years desire quit smoking despite physician 's advice currently smoke least 5 cigarette per day . Mild moderate , stable , allergic asthma define American Thoracic Society ( ATS ) criteria 1 History episodic wheeze shortness breath Subjects currently receive inhale shortacting bronchodilator treatment asthma . History symptoms significant autoimmune , hematological , neurological disease , include transient ischemic attack ( TIA ) , stroke , seizure disorder , behavioural disturbance judge clinically significant Investigator History serious adverse reaction hypersensitivity corticosteroid Abnormal chest Xray judge clinically significant Pregnant lactate positive plasma pregnancy test Use oral/parenteral/inhaled corticosteroid within last 28 day injectable depot corticosteroid within last 6 week . Use asthmarelated medication within 1 month Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Smokers</keyword>
	<keyword>Adults</keyword>
	<keyword>Inflammatory marker</keyword>
</DOC>